Adjunctive corticosteroid therapy is safe for bacterial corneal ulcers

Article

Using adjunctive corticosteroid therapy is safe on bacterial corneal ulcers and does not alter best spectacle-corrected visual acuity (BSCVA)Using adjunctive corticosteroid therapy is safe on bacterial corneal ulcers and does not alter best spectacle-corrected visual acuity (BSCVA).

Using adjunctive corticosteroid therapy is safe on bacterial corneal ulcers and does not alter best spectacle-corrected visual acuity (BSCVA), claims a study in the Archives of Ophthalmology.

Dr Muthiah Srinvasan and his team, Department of Corneal and External Diseases, Aravind Eye Care System, Madurai, India, conducted a randomized, placebo-controlled, double-masked multicentered clinical trial on 1769 patients with bacterial corneal ulcers. All patients were screened between September 1, 2006 and February 22, 2010.

The primary outcome was BSCVA at 3 months from patient enrolment and the secondary outcomes were infiltrate/scar size, re-epithelialization and corneal perforation.

In the subgroups of baseline BSCVA and ulcer location there were a significant number of corticosteroids observed. There was no significant difference in the 3-month BSCVA infiltrate scar/size, time to re-epithelialization and corneal perforation.

Patients with vision of counting fingers or worse at baseline presented with 0.17 logMAR better visual acuity with corticosteroids. Patients that were at baseline had 0.20 logMAR better visual acuity with corticosteroids.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.